➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Baxter
Johnson and Johnson
Medtronic
McKinsey

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AZACITIDINE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Azacitidine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004062 Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer Completed National Cancer Institute (NCI) Phase 1 1999-07-01 RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine. PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer.
NCT00004062 Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer Completed Lucille P. Markey Cancer Center at University of Kentucky Phase 1 1999-07-01 RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine. PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer.
NCT00004871 Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed National Cancer Institute (NCI) Phase 1 2000-05-01 RATIONALE: Azacitidine plus phenylbutyrate may help leukemia cells develop into normal white blood cells. PURPOSE: Phase I trial to study the effectiveness of combining azacitidine and phenylbutyrate in treating patients who have acute myeloid leukemia or myelodysplastic syndrome.
NCT00004871 Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed Sidney Kimmel Comprehensive Cancer Center Phase 1 2000-05-01 RATIONALE: Azacitidine plus phenylbutyrate may help leukemia cells develop into normal white blood cells. PURPOSE: Phase I trial to study the effectiveness of combining azacitidine and phenylbutyrate in treating patients who have acute myeloid leukemia or myelodysplastic syndrome.
NCT00005598 Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome Completed National Cancer Institute (NCI) Phase 2 2000-10-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Amifostine may improve blood counts in patients with myelodysplastic syndrome. Combining azacitidine with amifostine may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of azacitidine plus amifostine in treating patients who have myelodysplastic syndrome.
NCT00005598 Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome Completed University of Michigan Cancer Center Phase 2 2000-10-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Amifostine may improve blood counts in patients with myelodysplastic syndrome. Combining azacitidine with amifostine may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of azacitidine plus amifostine in treating patients who have myelodysplastic syndrome.
NCT00005639 Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment Completed National Cancer Institute (NCI) Phase 1 2000-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of azacitidine plus phenylbutyrate in treating patients with advanced or metastatic solid tumors that have not responded to previous treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Azacitidine

Condition Name

Condition Name for Azacitidine
Intervention Trials
Acute Myeloid Leukemia 77
Myelodysplastic Syndromes 77
Myelodysplastic Syndrome 62
Leukemia 37
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Azacitidine
Intervention Trials
Myelodysplastic Syndromes 219
Leukemia 209
Preleukemia 209
Leukemia, Myeloid, Acute 195
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Azacitidine

Trials by Country

Trials by Country for Azacitidine
Location Trials
France 78
Germany 71
Spain 64
Japan 60
Australia 59
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Azacitidine
Location Trials
Texas 115
New York 71
California 69
Florida 51
Maryland 48
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Azacitidine

Clinical Trial Phase

Clinical Trial Phase for Azacitidine
Clinical Trial Phase Trials
Phase 4 2
Phase 3 50
Phase 2/Phase 3 6
[disabled in preview] 372
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Azacitidine
Clinical Trial Phase Trials
Not yet recruiting 128
Recruiting 112
Completed 83
[disabled in preview] 105
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Azacitidine

Sponsor Name

Sponsor Name for Azacitidine
Sponsor Trials
National Cancer Institute (NCI) 76
Celgene Corporation 75
M.D. Anderson Cancer Center 51
[disabled in preview] 60
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Azacitidine
Sponsor Trials
Other 294
Industry 294
NIH 77
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Express Scripts
Dow
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.